A61K 47/6849
The antibody targeting a receptor, a cell surface antigen or a cell
Official title: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
A61K47/6849 (The antibody targeting a receptor, a cell surface antigen or a cell) appears on 2,779 US grants and 5,575 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,779
- Published applications
- 5,575
- Assignees
- 1,537
- Inventors
- 9,038
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 7 | 0 |
| 1994 | 2 | 0 |
| 1995 | 8 | 0 |
| 1996 | 11 | 0 |
| 1997 | 16 | 0 |
| 1998 | 27 | 0 |
| 1999 | 28 | 0 |
| 2000 | 25 | 0 |
| 2001 | 18 | 5 |
| 2002 | 27 | 31 |
| 2003 | 19 | 56 |
| 2004 | 16 | 60 |
| 2005 | 10 | 79 |
| 2006 | 26 | 65 |
| 2007 | 24 | 48 |
| 2008 | 26 | 59 |
| 2009 | 40 | 80 |
| 2010 | 30 | 83 |
| 2011 | 39 | 109 |
| 2012 | 44 | 106 |
| 2013 | 73 | 115 |
| 2014 | 86 | 169 |
| 2015 | 102 | 208 |
| 2016 | 140 | 304 |
| 2017 | 147 | 298 |
| 2018 | 187 | 301 |
| 2019 | 196 | 333 |
| 2020 | 193 | 309 |
| 2021 | 208 | 381 |
| 2022 | 181 | 422 |
| 2023 | 204 | 433 |
| 2024 | 213 | 538 |
| 2025 | 252 | 545 |
| 2026 | 145 | 438 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Muscle targeting complexes and formulations for treating facioscapulohumeral muscular dystrophy6 Oct 2026US 12,752,013 B2Dyne Therapeutics, Inc.
- Disruption of CD28-sialoside ligand complexes to enhance T cell activation6 Oct 2026US 12,752,014 B2The Scripps Research Institute
- Anti-galectin 3 antibodies and their use in epilepsy and related diseases6 Oct 2026US 12,752,015 B2Sunmed Therapeutic Limited
- Anti-Nectin-4 antibody, conjugate including the same, and application thereof6 Oct 2026US 12,753,230 B2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Bifunctional molecules for lysosomal targeting and related compositions and methods6 Oct 2026US 12,753,239 B2The Board of Trustees of the Leland Stanford Junior University
- Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof8 Oct 2026US 2026/0306651 A1MediLink Therapeutics (Suzhou) Co., Ltd.
- Lipid nanoparticles and methods of manufacture and use thereof8 Oct 2026US 2026/0306659 A1Ablynx N. V.
- Anti-ox40 antibody and uses thereof8 Oct 2026US 2026/0308267 A1Hutchison Medipharma Limited
- Novel lilrb2 antibodies and uses thereof8 Oct 2026US 2026/0309715 A1Board of Regents, The University of Texas System
- Systems and methods for targeted breast cancer therapies1 Oct 2026US 2026/0294809 A1American University of Sharjah
Most cited
By later US patents
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Chimeric antibody with specificity to human B cell surface antigen853US 5,500,362 AXoma Corporation · 1996
- Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma744US 5,736,137 AIDEC Pharmaceuticals Corporation · 1998
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Polypeptide variants521US 6,528,624 B1Genentech, Inc. · 2003